Bicycle Therapeutics (BCYC) Cash from Financing Activities (2018 - 2026)
Bicycle Therapeutics (BCYC) posted Cash from Financing Activities of -$54000.0 for Q1 2026, down 260.0% on a QoQ basis from -$15000.0 in Q4 2025, and down 31.71% year-over-year from -$79071.4 in Q1 2025.
Bicycle Therapeutics (BCYC) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at -$54000.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 31.71% year-over-year to -$54000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$144000.0 (down 100.03% YoY) and the FY2025 annual result came in at -$131000.0, down 100.03% from the prior year.
- Cash from Financing Activities was -$54000.0 for Q1 2026 at Bicycle Therapeutics, down from -$15000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $549.6 million in Q2 2024 and bottomed at -$31.9 million in Q3 2024.
- A 5-year average of $45.7 million and a median of $203000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 147466.67% — and 2024, when it slumped 113.61%.
- Bicycle Therapeutics' Cash from Financing Activities stood at $5.9 million in 2022, then tumbled by 93.44% to $386000.0 in 2023, then plunged by 47.41% to $203000.0 in 2024, then plunged by 107.39% to -$15000.0 in 2025, then plunged by 260.0% to -$54000.0 in 2026.
- Business Quant data shows BCYC's Cash from Financing Activities at -$54000.0 in Q1 2026, -$15000.0 in Q4 2025, and -$30000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Bicycle Therapeutics | 289.88 Mn | 289.88 Mn | - | -54,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -54,000.00 |
| Mar 31, 2026 | -54,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -45,000.00 |
| Jun 30, 2025 | -45,000.00 |
| Mar 31, 2025 | -41,000.00 |
| Mar 31, 2025 | -41,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Dec 31, 2024 | 203,000.00 |
| Sep 30, 2024 | -31.93 Mn |
| Sep 30, 2024 | -31.93 Mn |
| Jun 30, 2024 | 549.61 Mn |
| Jun 30, 2024 | 549.61 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Dec 31, 2023 | 386,000.00 |
| Dec 31, 2023 | 386,000.00 |